Shots:

• The US FDA has expanded the EUA of a booster dose of Pfizer-BioNTech COVID-19 vaccine to include children aged ≥12yrs. The dosage strength (30µg) of the booster dose is same as the dose approved in the primary series
• Additionally, the FDA action reduces time between completion of primary series and booster dose for all eligible individuals, and approves a third primary series dose for individuals aged 5-11yrs. with immunocompromise
• The US FDA previously approved booster dose in people aged ≥16yrs. and for ≥18yrs. of age who received other authorized COVID-19 vaccines

Ref: Pfizer | Image: The Wall Street Journal